Immunotherapy in Miscellaneous Medical Disorders Graves Ophthalmopathy, Asthma, and Regional Painful Syndrome
| Autor: | Romesh Khardori, Chaitanya Mamillapali, Michael Gonzales, Carmel Fratianni |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Allergy
medicine.medical_treatment Omalizumab Octreotide Antioxidants Piperazines Receptors Tumor Necrosis Factor Etanercept Antibodies Monoclonal Murine-Derived Risk Factors Azathioprine Medicine Anti-Asthmatic Agents Immunoglobulins Intravenous Radiotherapy Dosage General Medicine Decompression Surgical Antibodies Anti-Idiotypic Benzamides Cyclosporine Imatinib Mesylate Rituximab Immunotherapy Orbit Immunosuppressive Agents medicine.drug medicine.medical_specialty Pyridones Antibodies Monoclonal Humanized Graves' ophthalmopathy Selenium Humans Intensive care medicine Glucocorticoids Asthma business.industry Allergens medicine.disease Graves Ophthalmopathy Pyrimidines Imatinib mesylate Immunoglobulin G Immunology business Complex Regional Pain Syndromes |
| Zdroj: | Medical Clinics of North America. 96:635-654 |
| ISSN: | 0025-7125 |
| DOI: | 10.1016/j.mcna.2012.04.013 |
| Popis: | In Graves ophthalmopathy, immunotherapy is offering an opportunity of reducing bad outcomes that lead to disfigurement and impairment of vision. These therapies are not perfect; however, we now have a chance to achieve better outcomes. In asthma, immune therapy using passive immunity targeting key proinflammatory cytokine/chemokines and medications of their effects has opened an avenue of research into a safe and durable therapy. Omalizumab appears to be safe and effective in clinical use. In regional pain syndrome, immune mechanisms may be involved in sustaining long-standing pain, and IVIG may moderate pain sensitivity by reducing immune activation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|